Author

D. Pich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Assay:bulk RNA-seq· 5 Approach:experimental assay· 5 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:statistical model· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

W. Hammerschmidt· 6 shared P. Mrozek-Gorska· 4 shared A. Buschle· 2 shared E. Akidil· 2 shared M. Bouvet· 2 shared Y.-F. A. Chen· 2 shared A. Grundhoff· 1 shared A. Scialdone· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

W. Hammerschmidt

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Systematic analysis of Epstein-Barr virus genes and their individual contribution to virus production and composition

Y.-F. A. Chen, B. Mocanu, E. Akidil, D. Pich, J. Mautner, W. Hammerschmidt

This study systematically analyzes EBV genes to identify those that improve virus production, composition, and uptake by human B cells.

bioRxiv · Apr 26, 2021 · PreprintMicrobiology

Multiple viral microRNAs regulate interferon release and signaling early during infection with Epstein-Barr virus

M. Bouvet, S. Voigt, T. Tagawa, M. Albanese, Y.-F. A. Chen, Y. Chen, D. N. Fachko, D. Pich, C. Goebel, R. Skalsky, W. Hammerschmidt

This study identifies EBV miRNAs that regulate type I interferon responses in B cells and pDCs during early infection, dampening IFN- secretion.

bioRxiv · Dec 3, 2020Microbiology

Inducible transgene expression in PDX models in vivo identifies KLF4 as therapeutic target for B-ALL

W.-H. Liu, P. Mrozek-Gorska, T. Herold, L. Schwarzkopf, D. Pich, K. Völse, A.-K. Wirth, M. C. Melo-Narvaez, M. Carlet, W. Hammerschmidt, I. Jeremias

The paper uses PDX models to show KLF4 re-expression reduces B-ALL leukemia load and sensitizes tumors to chemotherapy, suggesting Azacitidine could regulate KLF4 as a therapeutic option.

bioRxiv · Mar 6, 2020Cancer Biology

The first days in the life of naïve human B-lymphocytes infected with Epstein-Barr virus

D. Pich, P. Mrozek-Gorska, M. Bouvet, A. Sugimoto, E. Akidil, A. Grundhoff, S. Hamperl, P. Ling, W. Hammerschmidt

This study identifies EBNA2 as essential for early EBV infection of naive B-cells, showing it drives activation, proliferation, and prevents cell death, while other latent genes have minimal or no effect during the pre-latent phase.

bioRxiv · Jun 11, 2019Microbiology

Epstein-Barr virus inactivates the transcriptome and disrupts the chromatin architecture of its host cell in the first phase of lytic reactivation

A. Buschle, P. Mrozek-Gorska, S. Krebs, H. Blum, F. M. Cernilogar, G. Schotta, D. Pich, T. Straub, W. Hammerschmidt

This study shows that EBV lytic reactivation causes global chromatin remodeling and transcriptome disruption in host cells before viral DNA replication.

bioRxiv · Mar 20, 2019Cell Biology

Epstein-Barr virus reprograms human B-lymphocytes immediately in the pre-latent phase of infection

P. Mrozek-Gorska, A. Buschle, D. Pich, T. Schwarzmayr, R. Fechtner, A. Scialdone, W. Hammerschmidt

This study shows EBV rapidly reprograms primary human B-lymphocytes transcriptionally within 24 hours of infection, leading to metabolic changes and cell cycle entry by day three.

bioRxiv · Dec 31, 2018Microbiology